Skip to main content
SpringerLink
Log in

Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma

  • Lymphoma (DO Persky, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Maintenance therapy has evolved as a strategy to prolong remissions in patients with diffuse large B cell lymphoma (DLBCL) or mantle cell lymphoma (MCL), typically following a more intensive therapy, such as induction therapy or stem cell transplantation. In randomized, controlled clinical trials, this approach has successfully prolonged overall survival in some MCL clinical settings, including after autologous stem cell transplantation and after R-CHOP induction, but has generally been unsuccessful in DLBCL. This most likely reflects differences in the biology and natural history of each disease. In DLBCL, a majority of patients are cured with frontline therapy, leaving fewer who can potentially benefit from maintenance. When the disease relapses, it is usually within the first 2 years and is usually clinically aggressive and difficult to control with low-intensity therapy. In contrast, nearly all patients with MCL will eventually relapse, and the disease may remain quiescent for many years. There may also be differences in sensitivity of minimal residual disease to maintenance treatments. Thus, future strategies to improve DLBCL treatments should focus on improved induction and possibly consolidation regimens rather than maintenance. In MCL, maintenance therapy will continue to play a role in the near future, although in both diseases, applying novel immunotherapies with the potential to eradicate residual disease clones persisting after induction may be the most successful strategy to improve patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Maurer MJ, Ghesquieres H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with Immunochemotherapy. J Clin Oncol. 2014;32:1066–73.

    Article  PubMed  PubMed Central  Google Scholar 

  2. •• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250–60. This study demonstrated an overall and progression-free survival benefit for younger patients with MCL that received 3 years of maintenance rituximab therapy following intensive induction and ASCT, compared with no maintenance therapy. This study established maintenance rituximab as a standard of care for MCL after ASCT.

    Article  PubMed  Google Scholar 

  3. Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood. 2013;121:48–53.

    Article  PubMed  CAS  Google Scholar 

  4. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687–93.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. • Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565–75. This study demonstrated a benefit of intensive cytarabine containing induction for younger patients with previously untreated MCL.

    Article  PubMed  CAS  Google Scholar 

  6. Diggs CH, Wiernik PH, Levi JA, Kvols LK. Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin’s disease. Cancer. 1977;39:1949–54.

    Article  PubMed  CAS  Google Scholar 

  7. Young RC, Canellos GP, Chabner BA, Schein PS, DeVita VT. Maintenance chemotherapy for advanced Hodgkin’s disease in remission. Lancet. 1973;1:1339–43.

    Article  PubMed  CAS  Google Scholar 

  8. Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, et al. Recommendations for clinical trial development in mantle cell lymphoma. J Natl Cancer Inst. 2017;109:djw263.

    Article  PubMed  Google Scholar 

  9. Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, et al. Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research. J Natl Cancer Inst. 2016;108:djw257.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016.

  11. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

    Article  PubMed  CAS  Google Scholar 

  12. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–7.

    Article  PubMed  CAS  Google Scholar 

  13. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.

    Article  PubMed  CAS  Google Scholar 

  14. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.

    Article  PubMed  CAS  Google Scholar 

  15. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–33.

    Article  PubMed  CAS  Google Scholar 

  16. Aviles A, Huerta J, Zepeda G, Guzman R, Diaz-Maqueo J. The role of maintenance therapy in the treatment of large-cell non-Hodgkin’s lymphoma. Acta Oncol. 1991;30:959–62.

    Article  PubMed  CAS  Google Scholar 

  17. Foon KA, Sherwin SA, Abrams PG, Longo DL, Fer MF, Stevenson HC, et al. Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon. N Engl J Med. 1984;311:1148–52.

    Article  PubMed  CAS  Google Scholar 

  18. Steis RG, Foon KA, Longo DL. Current and future uses of recombinant interferon alpha in the treatment of low-grade non-Hodgkin’s lymphoma. Cancer. 1987;59:658–63.

    Article  PubMed  CAS  Google Scholar 

  19. Aviles A, Diaz-Maqueo JC, Talavera A, Garcia EL, Nambo MJ. Maintenance therapy with interferon alfa 2b improves outcome in aggressive malignant lymphoma. Hematology. 1998;3:381–6.

    Article  PubMed  CAS  Google Scholar 

  20. Aviles A, Cleto S, Huerta-Guzman J, Neri N. Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens. Eur J Haematol. 2001;66:94–9.

    Article  PubMed  CAS  Google Scholar 

  21. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188–95.

    PubMed  CAS  Google Scholar 

  22. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927–32.

    PubMed  CAS  Google Scholar 

  23. Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000;95:3052–6.

    PubMed  CAS  Google Scholar 

  24. Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064–71.

    Article  PubMed  CAS  Google Scholar 

  25. Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984–92.

    Article  PubMed  CAS  Google Scholar 

  26. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–32.

    Article  PubMed  CAS  Google Scholar 

  27. • Jaeger U, Trneny M, Melzer H, et al. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica. 2015;100:955–63. This large study evaluated whether there is a benefit of treating patients with DLBCL with maintenance rituximab therapy following R-CHOP, and the results showed no significant difference in event-free or overall survival.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Witzens-Harig M, Benner A, McClanahan F, Klemmer J, Brandt J, Brants E, et al. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial. Br J Haematol. 2015;171:710–9.

    Article  PubMed  CAS  Google Scholar 

  29. Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009;20:1985–92.

    Article  PubMed  CAS  Google Scholar 

  30. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–90.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30:4462–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of Lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33:2803–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4952–7.

    Article  PubMed  Google Scholar 

  34. Thieblemont C, Tilly H, Gomes da Silva M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35:2473–81.

    Article  PubMed  Google Scholar 

  35. Ferreri AJ, Sassone M, Zaja F, et al. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. Lancet Haematol. 2017;4:e137–46.

    Article  PubMed  Google Scholar 

  36. Reddy NM, Greer JP, Morgan DS, Chen H, Park SI, Richards KL. A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma. Leukemia. 2017;31:241–4.

    Article  PubMed  CAS  Google Scholar 

  37. Chaiwatanatorn K, Stamaratis G, Opeskin K, Firkin F, Nandurkar H. Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab. Leuk Lymphoma. 2009;50:1666–75.

    Article  PubMed  CAS  Google Scholar 

  38. Riihijarvi S, Koivula S, Nyman H, Rydstrom K, Jerkeman M, Leppa S. Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. Mod Pathol. 2010;23:686–93.

    Article  PubMed  CAS  Google Scholar 

  39. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RCT, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68–74.

    Article  PubMed  CAS  Google Scholar 

  40. Hainsworth JD, Arrowsmith ER, McCleod M, Hsi ED, Hamid O, Shi P, et al. A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57:216–8.

    Article  PubMed  Google Scholar 

  41. • Crump M, Leppa S, Fayad L, et al. Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma. J Clin Oncol. 2016;34:2484–92. This large randomized, placebo-controlled study evaluated the efficacy of enzastaurin maintenance for 3 years in patients with DLBCL in first CR after R-CHOP but found no significant difference in DFS or OS.

    Article  PubMed  CAS  Google Scholar 

  42. Uddin S, Hussain AR, Siraj AK, Manogaran PS, al-Jomah NA, Moorji A, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006;108:4178–86.

    Article  PubMed  CAS  Google Scholar 

  43. Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25:341–7.

    Article  PubMed  CAS  Google Scholar 

  44. Johnston PB, LaPlant B, McPhail E, Habermann TM, Inwards DJ, Micallef IN, et al. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. Lancet Haematol. 2016;3:e309–16.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Witzig TE, LaPlant B, Habermann TM, McPhail E, Inwards DJ, Micallef IN, et al. High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance). Blood Cancer J. 2017;7:e576.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. •Witzig TE, Tobinai K, Rigacci L, et al. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol. 2017. This large randomized, placebo-controlled study evaluated the efficacy of everolimus maintenance for 1 year in patients with DLBCL in first CR after R-CHOP or R-EPOCH but found no significant difference in DFS or OS.

  47. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–6.

    Article  PubMed  CAS  Google Scholar 

  48. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, Meerwaldt JH, Hagenbeek A, van Glabbeke M, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1995;13:2819–26.

    Article  PubMed  CAS  Google Scholar 

  49. Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23:705–11.

    Article  PubMed  CAS  Google Scholar 

  50. Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003–8.

    Article  PubMed  CAS  Google Scholar 

  51. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520–31.

    Article  PubMed  CAS  Google Scholar 

  52. Ahmadi T, McQuade J, Porter D, Frey N, Loren AW, Goldstein SC, et al. Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. Bone Marrow Transplant. 2012;47:1082–6.

    Article  PubMed  CAS  Google Scholar 

  53. Graf SA, Stevenson PA, Holmberg LA, Till BG, Press OW, Chauncey TR, et al. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol. 2015;26:2323–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Mei MG, Cao TM, Chen L, Song JY, Siddiqi T, Cai JL, et al. Long-term results of high-dose therapy and autologous stem cell transplantation for mantle cell lymphoma: effectiveness of maintenance rituximab. Biol Blood Marrow Transplant. 2017;23:1861–9.

    Article  PubMed  CAS  Google Scholar 

  55. Rummel MJ, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016;34:7503.

    Article  Google Scholar 

  56. Bogner C, Peschel C, Decker T. Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach. Leuk Lymphoma. 2006;47:195–205.

    Article  PubMed  CAS  Google Scholar 

  57. Bogner C, Ringshausen I, Schneller F, Fend F, Quintanilla-Martinez L, Hacker G, et al. Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells. Br J Haematol. 2003;122:260–8.

    Article  PubMed  CAS  Google Scholar 

  58. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171:88–95.

    Article  PubMed  CAS  Google Scholar 

  59. Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol. 2007;18:116–21.

    Article  PubMed  CAS  Google Scholar 

  60. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–74.

    Article  PubMed  Google Scholar 

  61. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:667–75.

    Article  PubMed  CAS  Google Scholar 

  62. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676–84.

    Article  PubMed  CAS  Google Scholar 

  63. Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944–53.

    Article  PubMed  CAS  Google Scholar 

  64. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30:2946–55.

    Article  PubMed  CAS  Google Scholar 

  65. Dunleavy K, Grant C, Hessler J, et al. Bortezomib + DA-EPOCH-R induction therapy followed by maintenance bortezomib versus observation in newly diagnosed mantle cell lymphoma. Blood. 2012;120:3672.

    Google Scholar 

  66. Doorduijn JK, Minnema MC, Kersten MJ, et al. Bortezomib maintenance therapy after induction with R-CHOP, ARA-C and autologous stem cell transplantation in newly diagnosed MCL patients, results of a multicenter phase II HOVON study. Blood. 2015:339.

  67. Kaplan LD, Jung SH, Stock W, et al. Bortezomib maintenance (BM) versus consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB (Alliance) 50403. Blood. 2015;126:337.

    Google Scholar 

  68. Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, et al. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol. 2016;172:208–18.

    Article  PubMed  CAS  Google Scholar 

  69. Chen RW, Palmer JM, Popplewell L, et al. Phase II trial of bortezomib plus rituximab as maintenance therapy post ASCT for patients with mantle cell lymphoma. Blood. 2017;130:4515.

    Article  CAS  Google Scholar 

  70. Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373:1835–44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378:1211–23.

    Article  PubMed  CAS  Google Scholar 

  72. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Jerkeman M, Eskelund CW, Hutchings M, Räty R, Wader KF, Laurell A, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5:e109–16.

    Article  PubMed  Google Scholar 

  74. Chang JE, Carmichael LL, Kim K, Peterson C, Yang DT, Traynor AM, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network Study. Clin Lymphoma Myeloma Leuk. 2018;18:e61–7.

    Article  PubMed  Google Scholar 

  75. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009;27:4365–70.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N. Mailstop D3-100, Seattle, WA, 98109, USA

    Brian G. Till MD

Authors
  1. Brian G. Till MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian G. Till MD.

Ethics declarations

Conflict of Interest

Brian G. Till has received research support for the atezolizumab clinical trial from Genentech and has received research support as well as royalties on patents (pending and licensed) to Mustang Bio for CAR T cells.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Lymphoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Till, B.G. Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma. Curr. Treat. Options in Oncol. 19, 45 (2018). https://doi.org/10.1007/s11864-018-0561-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-018-0561-x

Keywords

Search

Navigation